Eric Lefkofsky is aiming to improve the treatment of cancer patients by giving researchers and clinicians easier and quicker access to resources that combines genomic information and therapeutic data. Lefkofsky is the co-founder and CEO of the startup company Tempus, which creates databases to help clinicians gather molecular date, clinical data, and therapeutic outcome response data into one source. The goal is to improve the free flow information between researchers, clinicians, nurses, and others so cancer patients can get the right health care treatment for their individual circumstances.
Lefkofsky is a graduate of the University of Michigan and the University of Michigan Law School. He is a Booth School of Business professor at the University of Chicago, but he is best known for being a serial entrepreneur who co-founded the global e commerce marketplace Groupon. Other companies Lefkofsky co-founded include Zest Health, Lightbank, Echo Global Logistics, and InnerWorkings. He is also a board member for several organizations, including World Business Chicago, the Art Institute of Chicago, Steppenwolf Theater Company, and Lurie Children’s Hospital.
In addition to his business ventures, Lefkofsky is a philanthropist who established Lefkofsky Family Foundation. He established this charitable foundation in 2006 with his wife Liz with the purpose of improving the quality of life for people in the communities the foundation serves. The foundation helps to provide people with access to a quality education, improve basic human rights, advance cancer research, and to expand artistic programs. The Lefkofsky Family Foundation is committed to caring for the well-being of others, eradicating cancer, and providing the city of Chicago with a strong cultural foundation in the following: http://www.bizjournals.com/chicago/news/2016/10/04/groupons-eric-lefkofsky-returns-to-the-forbes-400.html click here.
Lefkofsky was inspired to form Tempus after his wife’s breast cancer diagnosis. He noticed clinicians didn’t have readily available access to data on how certain treatments affect certain populations of cancer patients. He would like to have electronic medical records used in a way that combines all patient data so that clinicians can see the relationship between treatments and results.
Ultimately, Lefkofsky would like to see this process move beyond oncology research and be used on people who suffer from neurological disorders.